Blood Product & IVIG Infusions in Melbourne
Blood transfusion and intravenous immunoglobulin (IVIG) are supportive treatments used across haematology, oncology and immune-mediated conditions. They are very different therapies: blood transfusion replaces specific blood components such as red cells or platelets, while IVIG is a concentrated preparation of antibodies donated from many screened plasma donors and is used to modify immune activity or replace immunoglobulin in selected patients.
These therapies are prescribed only when there is a clear indication, because the potential benefit must be balanced against risks, supply considerations and alternative treatments.
Red cell transfusion is used when anaemia is severe enough to cause symptoms or physiological risk and when waiting for the body to recover or for iron/vitamin treatment to work is not appropriate. The decision is not based on one haemoglobin threshold alone; symptoms, heart or lung disease, bleeding, rate of decline and treatment goals matter. Before transfusion, blood group and compatibility testing is performed. Patients are monitored during the infusion for fever, rash, breathing difficulty, circulatory overload and other transfusion reactions.
Platelets may be transfused when the platelet count is very low or when there is clinically significant bleeding, particularly in patients with bone marrow failure, leukaemia or after intensive treatment. Platelet transfusion is not routinely useful for every cause of thrombocytopenia; for example, immune thrombocytopenia is usually treated by addressing the immune process unless there is major bleeding or another urgent indication. The haematologist considers the diagnosis, platelet count, bleeding status and planned procedures.
IVIG has several haematological uses. It can increase platelet counts temporarily in immune thrombocytopenia, is used in selected autoimmune blood disorders and can provide antibody replacement for some patients with significant secondary immunodeficiency and recurrent infections. The dose and schedule depend on the indication. Common infusion effects include headache, chills, fatigue or nausea, while less common complications include thrombosis, kidney injury, haemolysis or aseptic meningitis. Risk factors are assessed before treatment and infusion rates can be adjusted if reactions occur.
All blood products and immunoglobulin products are administered under established transfusion or infusion protocols. Identity checks, compatibility testing where relevant, baseline observations and monitoring during treatment are important safeguards. Patients should report new fever, rash, chest or back pain, breathlessness, severe headache or feeling suddenly unwell. Some reactions can occur after leaving the unit, so patients are also given advice about when to seek urgent medical attention.
The need for transfusion is reviewed in the context of the underlying condition. For chronic anaemia, the team also asks whether iron deficiency, haemolysis, marrow failure or active bleeding can be treated directly. For recurrent low platelets, the cause is assessed rather than simply using transfusion as a way to normalise a number.
Before IVIG is prescribed, the indication and expected treatment goal should be clear. In immune conditions, IVIG can provide a rapid but sometimes temporary response and may be used as a bridge while another treatment takes effect. In antibody deficiency, immunoglobulin levels, infection history and response to vaccination may form part of the assessment.
Patients who need repeated supportive treatment benefit from a plan that links transfusion thresholds or IVIG schedules to symptoms and clinical goals. This avoids unnecessary treatment while ensuring therapy is available when it is likely to help. Blood counts and other relevant tests are monitored between infusions.
Northern Blood & Cancer Care works with Northern Private Hospital and Northern Health day treatment services to coordinate transfusions and infusions. Where a patient is undergoing active chemotherapy or treatment for a blood cancer, supportive therapy is integrated into the same overall treatment plan.
The Haematology specialists associated with this service include:
Blood products and IVIG are most effective when used for a clearly defined clinical reason. Northern Blood & Cancer Care’s haematologists assess the underlying disorder, determine when transfusion or immunoglobulin is likely to help, and coordinate treatment through hospital day services as part of the patient’s broader haematology or cancer care plan.
Northern Blood & Cancer Care brings together a highly experienced team of haematologists, medical oncologists and specialist physicians, with consultations available at Northern Private Hospital in Epping.
Contact our team to arrange an appointment or discuss a referral.
